PAM
ANIK icon

Princeton Alpha Management’s Anika Therapeutics ANIK Stock Holding History

Princeton Alpha Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-7,606
Closed -$340K – 763
2016
Q1 		$340K Buy
+7,606
New +$309K 0.06% 470

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.57B AUM 19.49% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Princeton Alpha Management's ANIK Position: Q2 2016 in Review

Princeton Alpha Management sold out of Anika Therapeutics (ANIK) in Q2 2016, closing a stake of 7,606 shares — an estimated $340K sold.

Princeton Alpha Management first reported a position in ANIK in Q1 2016 and held it in 1 quarter. The position peaked at $340K in Q1 2016. 160 funds tracked by Wall St. Rank hold ANIK as of Q2 2016.

  • Princeton Alpha Management reported no remaining Anika Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Princeton Alpha Management sold 7,606 Anika Therapeutics shares in Q2 2016, an estimated $340K.
  • Princeton Alpha Management first reported a position in Anika Therapeutics in Q1 2016 and held it in 1 quarter.
  • Princeton Alpha Management's Anika Therapeutics position peaked at $340K in Q1 2016.
  • 160 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2016.

Based on Princeton Alpha Management's 13F filing for Q2 2016, filed 5 Aug 2016.